• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Madrigal Pharmaceuticals Inc. (Amendment)

    12/13/23 4:05:57 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDGL alert in real time by email
    SC 13D/A 1 d510843dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)*

     

     

    Madrigal Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, Par Value $0.0001 Per Share

    (Title of Class of Securities)

    558868105

    (CUSIP Number)

    Susan Vuong

    Chief Financial Officer

    Bay City Capital LLC

    1000 4th Street, Suite 500

    San Rafael, CA 94901

    (415) 321-9236

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 7, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See section 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a person’s initial filing on this form with respect to subject class of securities, and for any subsequent amendment containing information which would alter disclosures in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 558868105

     

      1.    

      Names of Reporting Persons

     

      Fred B. Craves

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      566,383

         8.   

      Shared Voting Power

     

      1,261

         9.   

      Sole Dispositive Power

     

      566,383

       10.   

      Shared Dispositive Power

     

      1,261

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      567,644

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      2.9%

    14.  

      Type of Reporting Person (See Instructions)

     

      IN


    CUSIP No. 558868105    

     

      1.    

      Names of Reporting Persons

     

      Bay City Capital LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      1,261

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      1,261

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,261

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      0%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. 558868105

     

      1.    

      Names of Reporting Persons

     

      Bay City Capital Management IV LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      0%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. 558868105

     

      1.    

      Names of Reporting Persons

     

      Bay City Capital Fund IV, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      0%

    14.  

      Type of Reporting Person (See Instructions)

     

      PN


    EXPLANATORY NOTE

    This Amendment No. 6 (“Amendment No. 6”) relates to the shares of common stock, par value $0.0001 per share (“Common Stock”), of Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”). This Amendment No. 6 amends and supplements the statement on Schedule 13D originally filed with the United States Securities and Exchange Commission on July 29, 2016 (as amended to date, the “Statement”). All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Statement.

    Item 3. Source and Amount of Funds or Other Consideration

    Item 3 of the Statement is amended and supplemented by inserting the following information:

    On June 16, 2022, Dr. Craves received options to purchase 9,470 shares of Common Stock from the Issuer as compensation for his service as a director of the Issuer. The options vested as to 100% of underlying shares of Common Stock on June 16, 2023.

    Item 4. Purpose of Transaction

    Item 4 of the Statement is amended and supplemented by inserting the following information:

    On December 7, 2023, Fund IV and BCC made in-kind transfers, without the payment of any consideration, of 1,510,521 shares and 46,073 shares, respectively, of Common Stock to their partners and employees.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Statement is amended and restated in its entirety as follows:

    (a) – (b)

    The following sets forth, as of the date of this Amendment No. 6, the aggregate number of shares and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition of as of the date hereof, based on 19,742,646 shares of Common Stock outstanding as of November 1, 2023.

     

    Reporting Person

       Amount
    beneficially
    owned
         Percent
    of class
        Sole power
    to vote or
    to direct
    the vote
         Shared
    power to
    vote or to
    direct the
    vote
         Sole
    power to
    dispose or
    to direct
    the
    disposition
         Shared
    power to
    dispose or
    to direct
    the
    disposition
     

    Fred B. Craves, Ph.D. (1)

         567,644        2.9 %      566,383        1,261        566,383        1,261  

    BCC

         1,261        0 %      0        1,261        0        1,261  

    Management IV

         0        0 %      0        0        0        0  

    Fund IV

         0        0 %      0        0        0        0  

     

    (1)

    The shares reported in the table above include: (i) 1,261 shares of Common Stock held of record by BCC; (ii) 413,362 shares of Common Stock held of record by Dr. Craves; (iii) 77,959 shares of Common Stock issuable upon exercise of stock options held by Dr. Craves that are exercisable within 60 days of the date hereof; (iv) 57,062 shares of Common Stock held by Dr. Craves through a grantor retained annuity trust and (v) 18,000 shares of Common Stock held by Dr. Craves through the Craves Family Foundation. Dr. Craves is the sole member of BCC, which is the manager of Management IV, which is the general partner of Fund IV. By virtue of these relationships, each of the foregoing entities and Dr. Craves may be deemed to share beneficial ownership of the shares reported herein. Each of them disclaims any such beneficial ownership.


    (c) Except as reported in Item 4 above, none of the Reporting Persons has effected any transactions in the Common Stock during the past sixty days.

    (d) None.

    (e) As of December 7, 2023, each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the Common Stock.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: December 13, 2023

    /s/ Fred Craves

    Fred Craves, Managing Director
    Bay City Capital LLC

    for himself and for Bay City Capital LLC, for and on behalf of Bay City Capital Management IV LLC in its capacity as manager thereof, and for and on behalf of Bay City Capital Fund IV, L.P. in its capacity as manager of Bay City Capital Management IV LLC, the general partner of Bay City Capital Fund IV, L.P.

    Get the next $MDGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDGL

    DatePrice TargetRatingAnalyst
    2/28/2025$236.00 → $422.00Neutral → Buy
    B. Riley Securities
    2/27/2025$400.00 → $405.00Buy
    H.C. Wainwright
    6/28/2024Neutral
    Cantor Fitzgerald
    6/11/2024$382.00Outperform
    Wolfe Research
    4/22/2024$150.00Underperform
    BofA Securities
    3/15/2024$155.00 → $270.00Sell → Neutral
    B. Riley Securities
    3/6/2024$382.00Buy
    Citigroup
    2/26/2024$155.00Neutral → Sell
    B. Riley Securities
    More analyst ratings

    $MDGL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Madrigal Pharmaceuticals Inc.

      10-Q - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)

      5/1/25 8:53:57 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Madrigal Pharmaceuticals Inc.

      8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)

      5/1/25 7:02:50 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Madrigal Pharmaceuticals Inc.

      DEFA14A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)

      4/29/25 4:21:46 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc.

      SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

      11/14/24 5:18:50 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Madrigal Pharmaceuticals Inc.

      SC 13G - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

      11/14/24 6:30:21 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Madrigal Pharmaceuticals Inc. (Amendment)

      SC 13D/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

      3/25/24 4:28:21 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Baker Bros. Advisors Lp bought $22,516,577 worth of shares (101,792 units at $221.20) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      12/14/23 6:10:59 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baker Bros. Advisors Lp bought $7,548,616 worth of shares (34,578 units at $218.31) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      12/14/23 6:09:05 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baker Bros. Advisors Lp bought $12,128,340 worth of shares (64,350 units at $188.47) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      11/21/23 6:15:19 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $MDGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $MDGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

      CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. EDT. The presentation will be webcast live and may be accessed here or by visiting Madrigal's Investor Relations Events and Presentations page. A replay of the webcast will be available after the event. About MadrigalMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Ma

      6/2/25 8:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

      Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk categories by year twoPatients achieved a mean 6.7 kPa reduction in liver stiffness, which was statistically significant compared to baseline CONSHOHOCKEN, Pa., May 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced positive two-year results from the open-label compensated MA

      5/10/25 7:15:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

      First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marketable securities of $848.1 million at March 31, 2025Company to host conference call today, May 1, 2025, at 8 a.m. EDT CONSHOHOCKEN, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.

      5/1/25 7:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Madrigal Pharmaceuticals from Neutral to Buy and set a new price target of $422.00 from $236.00 previously

      2/28/25 8:25:11 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Madrigal Pharmaceuticals with a new price target

      H.C. Wainwright reiterated coverage of Madrigal Pharmaceuticals with a rating of Buy and set a new price target of $405.00 from $400.00 previously

      2/27/25 6:40:20 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Madrigal Pharmaceuticals

      Cantor Fitzgerald initiated coverage of Madrigal Pharmaceuticals with a rating of Neutral

      6/28/24 7:43:43 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

      Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity

      3/14/24 3:35:50 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Financials

    Live finance-specific insights

    See more
    • Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

      First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marketable securities of $848.1 million at March 31, 2025Company to host conference call today, May 1, 2025, at 8 a.m. EDT CONSHOHOCKEN, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.

      5/1/25 7:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

      Patients achieved a mean 6.7 kPa reduction in liver stiffness as measured by vibration-controlled transient elastography (VCTE); this represents the largest reduction in liver stiffness reported in a compensated MASH cirrhosis patient population 51% of patients achieved a ≥25% reduction in liver stiffness; a reduction of this magnitude has been associated with reduced progression to end-stage liver diseaseCompany to review topline data during its fourth-quarter and full-year 2024 financial results conference call today, February 26, 2025, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused

      2/26/25 6:30:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

      Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered lives require biopsy Completed enrollment of clinical outcomes study of Rezdiffra in patients with compensated NASH/MASH cirrhosisReports cash, cash equivalents, restricted cash and marketable securities of $1.0 billion at September 30, 2024Company to host conference call today, October 31, 2024, at 8 a.m. EDT CONSHOHOCKEN, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic stea

      10/31/24 7:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

      Fred Craves, Ph.D. to retire from Madrigal's Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn ("Jackie") Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025. Julian Baker, Chairman of the Board of Directors, stated, "I am delighted to welcome Jackie Fouse to Madrigal. Jackie is an accomplished biotech executive who brings more than 30 years of healthcare industry and finance experience

      3/11/25 8:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

      CONSHOHOCKEN, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced the appointment of Michael R. Charlton, M.B.B.S., F.R.C.P., as Senior Vice President, Clinical Development, effective October 1, 2024. Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal, stated, "I am thrilled to have Dr. Charlton joining the Madrigal team; his deep experience as a researcher and clinician treating patients with NASH will bring powerful new insights and ca

      10/1/24 8:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

      CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Shannon is an outstanding leader who brings a wealth of expertise to her new role as General Counsel. She joined the Madrigal team in 2024 as Chief Compliance Officer and played an instrumental role guiding the company through a period of rapid growth. I feel privileged to be working with Shannon and the other members of our leader

      8/2/24 7:00:21 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Soergel David was granted 7,545 shares (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      5/16/25 6:23:51 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Soergel David

      3 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      4/24/25 5:03:13 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Craves Fred B exercised 15,470 shares at a strike of $82.90 and sold $5,082,480 worth of shares (15,470 units at $328.54) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      3/14/25 4:25:06 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care